MACROGENICS INC (MGNX) Stock Price, Quote, News and Overview
NASDAQ:MGNX - Nasdaq - US5560991094 - Common Stock - Currency: USD
MGNX Quote, Performance and Key Statistics
NASDAQ:MGNX (5/5/2025, 11:53:19 AM)
1.66
-0.09 (-5.14%)
The current stock price of MGNX is 1.66 USD. In the past month the price increased by 52.17%. In the past year, price decreased by -88.83%.
MGNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 346.42B | ||
| AMGN | AMGEN INC | 13.39 | 149.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1737.91 | 129.57B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 127.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.66 | 65.36B | ||
| ARGX | ARGENX SE - ADR | 344.61 | 39.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.91B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.55B | ||
| NTRA | NATERA INC | N/A | 21.58B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.64B | ||
| BIIB | BIOGEN INC | 7.73 | 17.92B |
Related stock screener links
About MGNX
Company Profile
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 341 full-time employees. The company went IPO on 2013-10-10. The firm generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. The company is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Company Info
MACROGENICS INC
9704 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Scott Koenig
Employees: 341
Phone: 13012515172
MACROGENICS INC / MGNX FAQ
What is the stock price of MACROGENICS INC today?
The current stock price of MGNX is 1.66 USD. The price decreased by -5.14% in the last trading session.
What is the ticker symbol for MACROGENICS INC stock?
The exchange symbol of MACROGENICS INC is MGNX and it is listed on the Nasdaq exchange.
On which exchange is MGNX stock listed?
MGNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MACROGENICS INC stock?
14 analysts have analysed MGNX and the average price target is 5.92 USD. This implies a price increase of 256.39% is expected in the next year compared to the current price of 1.66. Check the MACROGENICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MACROGENICS INC worth?
MACROGENICS INC (MGNX) has a market capitalization of 104.73M USD. This makes MGNX a Micro Cap stock.
How many employees does MACROGENICS INC have?
MACROGENICS INC (MGNX) currently has 341 employees.
What are the support and resistance levels for MACROGENICS INC (MGNX) stock?
MACROGENICS INC (MGNX) has a support level at 1.75 and a resistance level at 1.8. Check the full technical report for a detailed analysis of MGNX support and resistance levels.
Is MACROGENICS INC (MGNX) expected to grow?
The Revenue of MACROGENICS INC (MGNX) is expected to decline by -77.09% in the next year. Check the estimates tab for more information on the MGNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MACROGENICS INC (MGNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MGNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MGNX, evaluating the profitability, health, valuation and growth aspects
- MACROGENICS INC (MGNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MACROGENICS INC (MGNX) Sales and EPS estimates to see what analysts future expectations are.
- MACROGENICS INC (MGNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MACROGENICS INC (MGNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MACROGENICS INC (MGNX) Stock Chart to make your own analysis
- MACROGENICS INC (MGNX) Latest news and press-releases to stay up to date.
Does MACROGENICS INC (MGNX) stock pay dividends?
MGNX does not pay a dividend.
When does MACROGENICS INC (MGNX) report earnings?
MACROGENICS INC (MGNX) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of MACROGENICS INC (MGNX)?
MACROGENICS INC (MGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
What is the Short Interest ratio of MACROGENICS INC (MGNX) stock?
The outstanding short interest for MACROGENICS INC (MGNX) is 9.2% of its float. Check the ownership tab for more information on the MGNX short interest.
MGNX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MGNX. When comparing the yearly performance of all stocks, MGNX is a bad performer in the overall market: 97.58% of all stocks are doing better.
MGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGNX. The financial health of MGNX is average, but there are quite some concerns on its profitability.
MGNX Financial Highlights
Over the last trailing twelve months MGNX reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 38.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.59% | ||
| ROE | -57.7% | ||
| Debt/Equity | 0 |
MGNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to MGNX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -173.31% and a revenue growth -77.09% for MGNX